Skip to main contentAI and Advanced
/
LAURUSLABS · NSEBSE SENSEX74,627.84+0.39%BSE |
NIFTY 5023,346.45+0.55%NSE |
NIFTY BANK56,368.6+0.14%NSE |
NIFTY IT29,143.85+0.19%NSE |
NIFTY AUTO27,302.8+1.52%NSE |
NIFTY FMCG45,775.65+0.48%NSE |
NIFTY PHARMA26,471.45+1.24%NSE |
NIFTY 50022,700.75+0.75%NSE |
LA
NSE · Equity shares · Biotechnology & Drugs24.10 · 1.26%
Laurus Labs LAURUSLABS
NSE:INR 1,929.6
BSE:INR 1,930.3
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
AI analysis and Advanced tools for LAURUSLABS
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 1,905.5
Day rangeINR 1,863.5 — INR 1,940.4
52-week rangeINR 810.75 — INR 1,981.8
Volume28.71 L
Market cap99,189.82
P/E74.91
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)6,812.9
Net Income (INR Cr)888.79
Rev Growth (5 Year %)7.19
EPS Growth (5 Year %)-2.09
P/E Ratio74.91
EPS16.54
Research path: Interpret Laurus Labs's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
LAURUSLABSLaurus Labs1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 10,511.19 | 9,335.57 | 8,387.03 |
| Accumulated Depreciation Total | -2,528.25 | -2,110.88 | -1,728.49 |
| Other Liabilities Total | 692.19 | 453.69 | 241.75 |
| Accrued Expenses | 37.89 | 29.34 | 24.81 |
| Long Term Debt | 611.34 | 645.58 | 798.23 |
| Common Stock Total | 107.97 | 107.85 | 107.79 |
| Other Equity Total | -28.36 | -22.46 | -18.81 |
| Other Current Assets Total | 4.55 | 46.88 | 3.89 |
| Prepaid Expenses | 27.45 | 29.28 | 28.05 |
| Total Assets | 10,511.19 | 9,335.57 | 8,387.03 |
| Current Portof LT Debt/Capital Leases | 303.01 | 340.96 | 327.72 |
| Additional Paid-In Capital | 764.73 | 732.84 | 717.08 |
| Cash | 112.66 | 91.11 | 121.81 |
| Total Equity | 5,300.06 | 4,472.56 | 4,110.95 |
| Long Term Investments | 309.27 | 233.26 | 123.98 |
| Retained Earnings(Accumulated Deficit) | 4,455.72 | 3,654.33 | 3,304.89 |
| Total Common Shares Outstanding | 53.99 | 53.93 | 53.9 |
| Property/Plant/Equipment Total-Gross | 7,407.47 | 6,426.84 | 5,776.02 |
| Tangible Book Valueper Share Common Eq | 93.27 | 78.01 | 71.35 |
| Goodwill Net | 246.3 | 246.3 | 246.3 |
| Total Liabilities | 5,211.13 | 4,863.01 | 4,276.08 |
| Total Debt | 2,518.48 | 2,763.73 | 2,577.4 |
| Cashand Short Term Investments | 112.66 | 99.54 | 138.94 |
| Total Receivables Net | 2,342.39 | 2,220.08 | 1,818.68 |
| Notes Payable/Short Term Debt | 1,492.64 | 1,715 | 1,389.29 |
| Deferred Income Tax | 29.38 | 31.87 | 57.04 |
| Accounts Receivable-Trade Net | 2,155.04 | 2,007.16 | 1,662.92 |
| Property/Plant/Equipment Total-Net | 4,879.22 | 4,315.96 | 4,047.53 |
| Minority Interest | 131.3 | 129.96 | 4.62 |
| Total Current Liabilities | 3,635.43 | 3,539.72 | 3,112.28 |
| Total Inventory | 2,342.16 | 1,936.54 | 1,845.41 |
| Accounts Payable | 1,278.44 | 977.08 | 1,051.24 |
| Other Currentliabilities Total | 523.45 | 477.34 | 319.22 |
| Total Long Term Debt | 722.83 | 707.77 | 860.39 |
| Intangibles Net | 18.4 | 19.32 | 19.02 |
| Other Long Term Assets Total | 71.77 | 56.64 | 54.08 |
| Note Receivable-Long Term | 157.02 | 131.77 | 61.15 |
| Total Current Assets | 4,829.21 | 4,332.32 | 3,834.97 |
| Capital Lease Obligations | 111.49 | 62.19 | 62.16 |
| Cash Equivalents | Not available | 8.43 | 17.13 |
Fundamentals
Valuation and ratios
Valuation
PEG Ratio22.99
Price to Sale Ratio14.56
Growth
Debt 5Yr CAGR %11.19
Margins
Operating Margin 12m21.28
Operating Margin 5y Avg16.89
Net Profit Margin 12m15
Net Profit Margin 5y10.72
Yield
Dividend Yield %0.11
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskBalanced risk
Board Risk31.45
Analyst consensus
ConsensusHold
Consensus score2.85
Analyst opinions13
Strong Sell count1
Sell count3
Hold count4
Buy count3
Strong Buy count2
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Sun Pharmaceutical Industries | INR 1,944 | 4.66 L | 38.4 | — |
| Divi's Laboratories | INR 8,291.55 | 2.20 L | 73.32 | — |
| Torrent Pharmaceuticals | INR 4,965 | 1.89 L | 72.73 | — |
| Cipla | INR 1,475 | 1.19 L | 27.57 | — |
| Zydus Lifesciences | INR 1,106.25 | 1.10 L | 21.19 | — |
Shareholding
Ownership
- Promoter
- 27.47%
- FII
- 28.00%
- MF
- 10.15%
- Other
- 34.38%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Laurus Labs - MFs kept buying these 14 stocks for 3 quarters; shares surged up to 101% - The Economic TimesMarket news · 21 Jul 2026, 1:42 pm
Laurus Labs - MFs kept buying these 14 stocks for 3 quarters; shares surged up to 101% The Economic Times
Laurus stock holds firm as recent earnings and portfolio strategy set the tone - ad-hoc-news.deMarket news · 20 Jul 2026, 12:53 am
Laurus stock holds firm as recent earnings and portfolio strategy set the tone ad-hoc-news.de
MSCI India rejig: Why Adani Green, Groww and Laurus Labs are on investors’ radar - The Economic TimesMarket news · 16 Jul 2026, 10:06 am
MSCI India rejig: Why Adani Green, Groww and Laurus Labs are on investors’ radar The Economic Times
laurus labs - Biocon among 4 midcap stocks that hit 52-week highs and rallied up to 21% in a month - The Economic TimesMarket news · 15 Jul 2026, 1:39 am
laurus labs - Biocon among 4 midcap stocks that hit 52-week highs and rallied up to 21% in a month The Economic Times
Eternal, Adani Energy, And Astral: Stocks To Watch Ahead Of MSCI's August Review — Check Axis Capital's List - NDTV ProfitMarket news · 14 Jul 2026, 1:56 pm
Eternal, Adani Energy, And Astral: Stocks To Watch Ahead Of MSCI's August Review — Check Axis Capital's List NDTV Profit
Trade Spotlight: How should you trade Route Mobile, Coforge, Divis Labs, BEML, Voltas, Laurus Labs, and... - Moneycontrol.comMarket news · 14 Jul 2026, 12:30 pm
Trade Spotlight: How should you trade Route Mobile, Coforge, Divis Labs, BEML, Voltas, Laurus Labs, and... Moneycontrol.com
Corporate actions
Events
- board MeetingsQuarterly Results
- annual General MeetingAGM
- dividendRs.1.2000 per share(60%)Interim Dividend
- board MeetingsAudited Results & Interim Dividend
- board MeetingsQuarterly Results
- dividendRs.0.8000 per share(40%)Interim Dividend
- board MeetingsQuarterly Results & Interim Dividend
- board MeetingsQuarterly Results
Rusaka Markets Community
Discussion and sentiment for Laurus Labs
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Checking your Rusaka Markets account…
Company profile
Business information
What the company does
Laurus Labs Limited is an India-based company. The Company is a pharmaceutical manufacturing organization. It is engaged in developing and manufacturing active pharmaceutical ingredients (APIs) and intermediates. It supplies anti-retroviral APIs and intermediates. It provides contract and custom manufacturing solutions, allowing client organizations to outsource various stages of the manufacturing process. It is also engaged in development and manufacturing of animal-origin-free recombinant proteins, growth factors, and cell-culture media supplements catering to the needs of stem cells and regenerative medicine, vaccines and biological drugs, cultured meat, and cell-culture media manufacturing. It offers precision fermentation as a contract development and manufacturing organization (CDMO) service. Its service is offered to protein companies and bio-manufacturers operating across healthcare, food, nutrition, personal care, and bio-based materials markets.
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- LAURUSLABS
- BSE Code
- 540222
Questions
Stock FAQ
What is the symbol and ISIN of Laurus Labs?
Laurus Labs has the symbol LAURUSLABS and ISIN - INE947Q01028.
What is the current price of Laurus Labs?
Laurus Labs is currently trading at INR 1,929.60.
What are the year high and year low of Laurus Labs?
Laurus Labs has a year high of INR 1,981.80 and a year low of INR 810.75.
What is the market capitalization of Laurus Labs?
Laurus Labs has a market capitalization of INR 99,189.82 crore.
What is the P/E ratio of Laurus Labs?
Laurus Labs has a P/E ratio of 74.91.
What is the dividend yield of Laurus Labs?
Laurus Labs has a dividend yield of 0.11%.
How is the financial performance of Laurus Labs based on revenue, net income, and EPS?
Laurus Labs has revenue of INR 6,812.90 crore, net income of INR 888.79 crore, and EPS of INR 20.23.
What is the book value of Laurus Labs?
Laurus Labs has a book value of NA.
What is the debt-to-equity ratio of Laurus Labs?
Laurus Labs has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Laurus Labs?
Laurus Labs has a price-to-book ratio of NA and a price-to-sales ratio of 14.56.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.